NCT05648812

Brief Summary

The aim of our study is to investigate changes of brain perfusion and elasticity in neonates during the time that a neonate is adapting to live outside the womb and during diseases that are suspected to affect neonatal brain perfusion. We use contrast enhanced ultrasound (sulphur hexafluoride) and ultrasound-assisted elastography to evaluate the state of brain perfusion. We will study neonates recruited from the Neonatal Units of Turku University Hospital.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P25-P50 for phase_3

Timeline
43mo left

Started Jan 2024

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Jan 2024Dec 2029

First Submitted

Initial submission to the registry

December 5, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

December 13, 2022

Completed
1.1 years until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2029

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

January 15, 2026

Status Verified

January 1, 2026

Enrollment Period

5.5 years

First QC Date

December 5, 2022

Last Update Submit

January 13, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Repeated qualitative and quantitative assessment of neonatal brain perfusion using contrast-enhanced ultrasound of the brain

    Visual assessment of contrast enhancement on both brain hemispheres. Quantitative analysis of proper ultrasound parameters, such as wash-in and wash-out curves, during the adaptive period and during different brain pathologies and their treatment.

    20 days

Secondary Outcomes (2)

  • Repeated qualitative assessment of neonatal brain elasticity using ultrasound-guided shear wave elastography

    20 days

  • Comparing the brain perfusion in neonates with no diseases affecting brain perfusion and neonates with different brain pathologies

    20 days

Study Arms (4)

Term neonates

ACTIVE COMPARATOR

Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography, cardiac ultrasound To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with no suspected brain pathology using CEUS. Later, different patient groups could be compared to infants with no suspected brain pathology. Other Names: • SonoVue

Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastographyDrug: Sulfur Hexafluoride

Neonatal asphyxia

EXPERIMENTAL

Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in neonates after birth asphyxia Other Names: • SonoVue

Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastographyDrug: Sulfur Hexafluoride

Neonatal stroke

EXPERIMENTAL

Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion after neonatal stroke Other Names: • SonoVue

Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastographyDrug: Sulfur Hexafluoride

Other neonatal brain pathologies

EXPERIMENTAL

Diagnostic Test: Brain ultrasound, brain contrast enhanced ultrasound, brain ultrasound elastography To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography Drug: Sulfur Hexafluoride To evaluate brain perfusion in infants with other type (no asphyxia, stroke or preterm birth related) of brain pathology, like hydrocephalus, hemorrhage or central nervous system infection Other Names: • SonoVue

Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastographyDrug: Sulfur Hexafluoride

Interventions

To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography

Neonatal asphyxiaNeonatal strokeOther neonatal brain pathologiesTerm neonates

To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology

Also known as: SonoVue
Neonatal asphyxiaNeonatal strokeOther neonatal brain pathologiesTerm neonates

Eligibility Criteria

Age1 Minute - 6 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Babies less than 7 months treated at the neonatal units of Turku University hospital

You may not qualify if:

  • Pre-known genetic disease
  • Difficult congenital malformations that need surgical treatment
  • Central nervous system tumors
  • Weight less than 2,5 kg during examination
  • Medical history of SonoVue hypersensitivity
  • Uncontrolled systemic hypertension
  • Systolic pulmonary artery pressure \> 90 mmHg
  • Unstable cardiovascular state

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Turku University Hospital

Turku, Southwestern Finland, 20520, Finland

RECRUITING

MeSH Terms

Interventions

Sulfur Hexafluoridecontrast agent BR1

Intervention Hierarchy (Ancestors)

FluoridesHydrofluoric AcidFluorine CompoundsInorganic ChemicalsGasesSulfur Compounds

Study Officials

  • Tiina Laurikainen

    Turku University Hospital

    PRINCIPAL INVESTIGATOR
  • Riitta Parkkola

    Turku University Hospital

    STUDY DIRECTOR
  • Vilhelmiina Parikka

    Turku University Hospital

    STUDY CHAIR
  • Jussi Hirvonen

    Turku University Hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 5, 2022

First Posted

December 13, 2022

Study Start

January 1, 2024

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

December 1, 2029

Last Updated

January 15, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations